Table 1.
Compounds screened versus SARS-CoV-2: Vero E6 cells were infected with nCoV- 2019BetaCoV/Wuhan/WIV04/2019 at a multiplicity of infection (MOI) of 0.05 [14]
| Molecule | Class | EC50 (μM) | CC50 (μM) | SI | FDA status |
|---|---|---|---|---|---|
 Ribavirin |
Antiviral for hepatitis C | 109.5 | >400 | 3.65 | Approved |
 Penciclovir |
Antiviral for herpesvirus | 95.96 | >400 | 4.17 | Approved |
 Favipiravir |
Broad-spectrum antiviral | 61.88 | >400 | 6.46 | Experimental |
 Nafamostat |
Anticoagulant agent | 22.50 | >100 | 4.44 | Approved |
 Nitazoxanide |
Anthelmintic agent | 2.21 | 35.53 | 16.76 | Approved |
 Remdesivir |
Antiviral agent | 0.77 | >100 | 129.87 | Phase II/III |
 Chloroquine |
Antimalarial agent | 1.13 | >100 | 88.50 | Approved |